The Claim
In patients with coronary artery disease undergoing percutaneous coronary intervention, baseline high-sensitivity C-reactive protein levels between 2 and 3 mg/L are associated with a 44% higher risk of major adverse cardiac and cerebrovascular events within one year compared to baseline levels below 2 mg/L.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Patients with coronary artery disease who have high-sensitivity C-reactive protein levels between 2 and 3 mg/L before undergoing percutaneous coronary intervention have a 44% higher rate of major heart or brain events within one year than those with levels below 2 mg/L.
See the scientific wording
In patients with coronary artery disease undergoing percutaneous coronary intervention, baseline high-sensitivity C-reactive protein levels between 2 and 3 mg/L are associated with a 44% higher risk of major adverse cardiac and cerebrovascular events within one year compared to levels below 2 mg/L, suggesting that even moderate inflammation elevation may confer increased cardiovascular risk.
When inflammation markers rise slightly, they trigger immune cells to stick to blood vessel walls, damage the inner lining, and make clots more likely to form, which can block arteries and cause heart attacks or strokes.
What the research says
1 studyFor heart patients who got stents, those with a slightly elevated inflammation marker (between 2 and 3 mg/L) had a 44% higher chance of having a heart attack, stroke, or dying within a year than those with lower levels — and the study directly found this exact result.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.